Clinical trialNCT01005329CompletedPhase 2Interventional

Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer

SponsorNational Cancer Institute (NCI)Enrollment34Endometrial AdenocarcinomaEndometrial Adenosquamous CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Serous AdenocarcinomaStage IA Uterine Corpus Cancer AJCC v7Stage IB Uterine Corpus Cancer AJCC v7+6 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies the side effects of giving intensity-modulated radiation therapy together with cisplatin and bevacizumab followed by carboplatin and cisplatin and to see how well they work in treating patients who have undergone surgery for high-risk endometrial cancer. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, carboplatin, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving intensity-modulated radiation therapy together with chemotherapy and bevacizumab after surgery may kill any tumor cells that remain after surgery.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Akila Viswanathan
Radiation Therapy Oncology Group
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

41 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

London Regional Cancer Program
London, Ontario, Canada
Mcgill University Department of Oncology
Montreal, Quebec, Canada

Hong Kong

Pamela Youde Nethersole Eastern Hospital
Chai Wan, Hong Kong

United States

Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California, United States
John Muir Medical Center-Walnut Creek
Walnut Creek, California, United States
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, United States
Poudre Valley Hospital
Fort Collins, Colorado, United States
Christiana Care Health System-Christiana Hospital
Newark, Delaware, United States
Baptist Md Anderson Cancer Center
Jacksonville, Florida, United States
Baptist Medical Center South
Jacksonville, Florida, United States
Integrated Community Oncology Network-Southside Cancer Center
Jacksonville, Florida, United States
University of Florida Health Science Center - Jacksonville
Jacksonville, Florida, United States
Integrated Community Oncology Network-Florida Cancer Center Beaches
Jacksonville Beach, Florida, United States
21st Century Oncology-Orange Park
Orange Park, Florida, United States
21st Century Oncology-Palatka
Palatka, Florida, United States
Bay Medical Center
Panama City, Florida, United States
Integrated Community Oncology Network-Flager Cancer Center
Saint Augustine, Florida, United States
John H Stroger Jr Hospital of Cook County
Chicago, Illinois, United States
Northwestern University
Chicago, Illinois, United States
Saint Vincent Anderson Regional Hospital/cancer Center
Anderson, Indiana, United States
Saint Vincent Hospital and Health Care Center
Indianapolis, Indiana, United States
Kansas City Nci Community Oncology Research Program
Prairie Village, Kansas, United States
University of Maryland/greenebaum Cancer Center
Baltimore, Maryland, United States
Central Maryland Radiation Oncology in Howard County
Columbia, Maryland, United States
Brigham and Women'S Hospital
Boston, Massachusetts, United States
Henry Ford Hospital
Detroit, Michigan, United States
West Michigan Cancer Center
Kalamazoo, Michigan, United States
Elliot Hospital
Manchester, New Hampshire, United States
Stony Brook University Medical Center
Stony Brook, New York, United States
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
Summa Akron City Hospital/cooper Cancer Center
Akron, Ohio, United States
Summa Barberton Hospital
Barberton, Ohio, United States
Flower Hospital
Sylvania, Ohio, United States
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Paoli Memorial Hospital
Paoli, Pennsylvania, United States
Radiation Therapy Oncology Group
Philadelphia, Pennsylvania, United States
Lankenau Medical Center
Wynnewood, Pennsylvania, United States
M D Anderson Cancer Center
Houston, Texas, United States
Huntsman Cancer Institute/university of Utah
Salt Lake City, Utah, United States
Wheeling Hospital/schiffler Cancer Center
Wheeling, West Virginia, United States

1 more site on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bevacizumab →Carboplatin →Cisplatin →Paclitaxel →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 6 Nov 2009
Primary completion: 30 Jun 2012
Completion: 22 Sept 2013
Last update posted: 15 Mar 2018
Registered enrollment: 34
Registry id: NCT01005329

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.